Lysodren is approved to treat patients with inoperable, functional or nonfunctional adrenocortical carcinoma (ACC), meaning adrenal cortex cancer that cannot be completely removed by surgery.

Specialists also use mitotane off label as part of adjuvant therapy after ACC surgery to reduce the risk of recurrence, and to control severe cortisol excess (Cushing’s syndrome) when surgery or radiation alone do not adequately control hormone overproduction; evidence for these uses comes mainly from observational studies and expert guidelines rather than large randomized trials.

In advanced ACC, mitotane can shrink or stabilize tumors in a minority of patients and more often improves hormone‑related symptoms; blood levels usually reach the target range after about 3–5 months, so benefits on tumor growth may take weeks to months to assess, while reductions in cortisol can occur earlier.

Overall response rates in ACC are modest (roughly 20–30% of patients have tumor shrinkage or clear stabilization), but some patients experience prolonged disease control, and mitotane remains the only drug specifically approved for ACC; it is often combined with other chemotherapy agents (such as etoposide, doxorubicin, and cisplatin) in more aggressive treatment regimens.

Compared with other systemic cancer therapies, Lysodren has a narrow therapeutic window and a very long half‑life, so careful dose titration and regular monitoring of blood mitotane levels are essential to balance potential benefits against toxicity.

Lysodren is an oral tablet (500 mg) taken by mouth, usually 3–4 times per day with food, ideally with meals that have some fat to improve absorption, and tablets should be swallowed whole without crushing, chewing, or splitting.

For adults with inoperable ACC, doctors typically start at a total daily dose of about 2,000–6,000 mg (for example, 500 mg four to twelve times per day divided into 3–4 doses) and then adjust the dose gradually based on tolerance, clinical response, and regular blood tests that measure mitotane levels, aiming for a target range of roughly 14–20 mg/L.

Some patients who are frail, older, or very small may start at a lower daily dose (for example, 500–2,000 mg/day) and increase more slowly to reduce early side effects; there is no fixed “maximum dose,” but doses are limited by tolerability and blood levels to avoid severe neurologic toxicity.

Because Lysodren suppresses adrenal hormone production, many patients need replacement corticosteroids (and sometimes mineralocorticoids), often at higher-than-usual doses, and they may require extra "stress" steroids and temporary interruption of Lysodren around major surgery, severe infections, or major injuries.

Due to its very long half‑life and accumulation in fat tissue, mitotane can remain in the body for weeks to months after stopping, so dose changes take time to show full effect and side effects may persist even after the drug is discontinued.

If you miss a dose, take it as soon as you remember unless it is almost time for your next scheduled dose; if it is close to the next dose, skip the missed dose and take the next dose at the usual time—do not double up to make up for a missed dose.

In case of overdose or if too many tablets are taken, seek emergency medical care or contact a poison control center right away, since there is no specific antidote and treatment focuses on monitoring, supportive care, and managing adrenal insufficiency or neurologic toxicity.

Common side effects (often in more than 1 in 10 patients) include loss of appetite, nausea, vomiting, diarrhea, abdominal discomfort, fatigue or weakness, dizziness or vertigo, drowsiness, mood changes or depression, skin rash, elevated cholesterol and triglycerides, and changes in thyroid or sex hormone levels; these effects can develop gradually as the drug accumulates and may range from mild to severe.

Serious adverse effects that need immediate medical attention include signs of adrenal insufficiency or adrenal crisis (severe weakness, vomiting, low blood pressure, confusion, or collapse, especially during infection, injury, or surgery), severe confusion or other neurologic problems (trouble walking, speaking, vision changes, extreme drowsiness), severe liver problems (dark urine, yellowing of skin or eyes, right‑upper belly pain), prolonged or unusual bleeding or bruising, very low white blood cell counts with infection signs (fever, sore throat), and severe allergic reactions.

Important warnings and precautions include a boxed warning for adrenal crisis during shock, severe trauma, or infection; patients often need steroid replacement and extra "stress‑dose" steroids during illness or surgery, and the drug may need to be held temporarily.

Pregnancy: Lysodren can harm an unborn baby; females who can become pregnant should have a pregnancy test before starting, avoid becoming pregnant, and use reliable nonhormonal contraception during treatment and for as long as mitotane remains detectable in the blood, because the drug can make hormonal birth control less effective and persists in body fat for months.

Breastfeeding is not recommended during treatment or while mitotane levels remain detectable because the drug passes into breast milk and may cause serious harm to a nursing child.

Use in children: effectiveness in pediatric patients has not been established, and reports describe potential long‑term effects on growth, puberty, and neuro‑psychological development; if used, it should be under the care of highly experienced specialists with close monitoring.

Use in older adults and in patients with liver or kidney disease requires extra caution and frequent monitoring, and Lysodren is generally not recommended in severe hepatic or renal impairment due to limited data and risk of accumulation.

Compared with many other oral cancer medicines, Lysodren has more frequent gastrointestinal, neurologic, and endocrine side effects and a higher risk of adrenal crisis, so it is usually prescribed and followed by centers experienced in adrenocortical carcinoma.

Patients and caregivers should promptly report troublesome or unexpected side effects to their healthcare team; in the United States, side effects can also be reported directly to the FDA MedWatch program by phone or online, which helps update safety information over time.

Lysodren strongly induces certain liver enzymes, especially CYP3A4, which can lower the levels and effectiveness of many other medicines, including some chemotherapy drugs, anti‑seizure medicines, some sedatives, certain blood pressure medicines, many immune‑suppressing drugs, and the benzodiazepine midazolam; doses of these other medicines may need adjustment or alternative drugs may be chosen.

It can significantly reduce the effect of warfarin and other blood thinners or, in some cases, alter bleeding risk, so blood‑clotting tests and clinical monitoring are needed when these drugs are used together.

Lysodren decreases the effectiveness of hormonal contraceptives (pills, patches, rings, some implants), so people who can become pregnant should use reliable nonhormonal contraception (such as a copper IUD or barrier methods) during treatment and while mitotane remains detectable in the blood.

Concomitant use with spironolactone is discouraged because spironolactone can interfere with mitotane’s action and has been associated with lower mitotane blood levels; other potassium‑sparing options or diuretics are usually preferred if needed.

Alcohol and other medicines that cause drowsiness or dizziness (such as some sleep aids, anxiety medicines, or opioid painkillers) can add to mitotane‑related sedation and neurologic side effects, so they should be used cautiously, if at all, and driving or operating machinery should be avoided if you feel sleepy or unsteady.

Lysodren alters the metabolism and blood measurements of cortisol and related steroids, which can complicate interpretation of adrenal or pituitary function tests; clinicians should take this into account when ordering and interpreting hormone tests.

Important precautions include avoiding use in patients with severe liver or kidney impairment when possible, using extra caution in those with bleeding disorders or planned surgery due to prolonged bleeding time, and very careful use or avoidance in pregnancy and breastfeeding because of the risk of fetal and neonatal toxicity.

Monitoring typically includes regular checks of mitotane blood levels, adrenal function (cortisol and ACTH), electrolytes, liver and kidney tests, blood counts, lipids, thyroid function, sex hormones in some patients, and neurologic assessments, with dose adjustments or treatment interruptions as needed based on results and side effects.

Q: What is Lysodren used for?
A: Lysodren is used to treat cancer of the adrenal cortex (adrenocortical carcinoma) that cannot be fully removed by surgery, whether or not the tumor is overproducing hormones.

Q: How long does it take for Lysodren to start working?
A: The drug builds up slowly in the body, so hormone levels may improve over weeks, but it often takes 3–5 months to reach target blood levels and see the full effect on tumor control.

Q: How should I take Lysodren tablets?
A: Take the tablets by mouth 3–4 times a day with food (preferably at the same times each day), swallow them whole without crushing or chewing, and follow the exact dosing schedule set by your specialist.

Q: Will I need other medicines while I am on Lysodren?
A: Many people need steroid replacement medicines because Lysodren lowers adrenal hormone production, and your doctor may also adjust or add other drugs to manage side effects, control blood pressure, or treat the cancer in combination with Lysodren.

Q: What should I do if I get sick or need surgery while taking Lysodren?
A: Contact your cancer team immediately, because you may need extra steroid doses and sometimes temporary interruption of Lysodren during serious infections, injuries, or surgery to prevent adrenal crisis.

Q: Can I become pregnant or breastfeed while taking Lysodren?
A: No; mitotane can harm an unborn baby and passes into breast milk, so effective nonhormonal birth control is needed during treatment (and for months afterward), and breastfeeding should be avoided until your doctors confirm that mitotane is no longer detectable in your blood.

Q: How are side effects and safety checked while I am on this medicine?
A: Your healthcare team will see you regularly for exams and blood tests to monitor mitotane levels, adrenal function, liver and kidney health, blood counts, cholesterol, and other hormones, and they will adjust your dose or pause treatment if problems arise.

Store Lysodren tablets at room temperature around 77°F (25°C), in the original tightly closed container, protected from excess heat, moisture, and direct light, and keep them out of reach of children and pets.

Swallow tablets whole; do not crush, split, or chew them, and caregivers who handle the tablets (especially broken tablets) should wear disposable gloves and wash hands afterward because this is a hazardous chemotherapy drug.

Do not use tablets that are damaged or show signs of deterioration, and do not keep medicine that is expired or no longer needed.

For disposal, do not throw Lysodren in household trash or flush it in the toilet; instead, use a pharmacy or community drug take‑back program, or follow your pharmacist’s or local waste authority’s instructions for disposing of hazardous medicines.